is a randomized, double-blinded, placebo controlled trial in 28 children
aged 6-14 with mild to moderate persistent asthma who received either
double their inhaled steroid dose or baseline inhaled steroid dose plus
placebo inhaler for the first three days of their asthma exacerbation.1
criteria included concurrent oral steroid use, long acting ß-agonist
use, cromlyn use, or history of ICU admission, recent inpatient stay,
or change in inhaled steroid dose in the previous 2 months to study
stratification for age and sex, the children were randomized to receive
one of two possible treatment sequences for serial exacerbations, placebo
than steroid, or steroid then placebo.
main outcomes of the study included morning and evening PEF, asthma
symptom scores, spirometric measurements, parental satisfaction, and
methods of the article were valid - patients were randomly allocated,
all patients were accounted for at the study end, the researchers were
blinded, and study groups were treated equally.
statistical significant difference (p < 0.05) was detected in any
outcome measure of the study between the increased and baseline inhaled
steroids groups (18 total paired asthma exacerbations).